Equus Receives Notice of Non-Compliance with New York Stock Exchange Share Price Rule
Equus has a six-month cure period following receipt of the notice, with continued listing subject to other NYSE standards.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Equus Total Return (NYSE: EQS) received a notice on October 6, 2026, of noncompliance with the NYSE minimum share-price rule. Its average closing price was below $1.00 over 30 consecutive trading days. The notice is a deficiency notice, not a delisting, and has no immediate effect on listing or trading.
Equus plans to notify the NYSE by October 20, 2026 of its intent to restore compliance and will consider alternatives, including a reverse stock split. During the six-month cure period following receipt, compliance requires a month-end closing price and a preceding 30-trading-day average of at least $1.00. Continued listing remains subject to other NYSE standards.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Minor pointListing and trading face no immediate impact; the notice is a deficiency notice, not delisting.
- Minor point. Forward-looking: it has not happened yet and may not happen.Compliance plan includes notifying the NYSE by October 20, 2026, and considering available remedies.
- Minor point. Forward-looking: it has not happened yet and may not happen.Business operations and SEC reporting are not expected by Equus to be affected.
Negative
- Moderate pointAverage closing share price below $1.00 over 30 consecutive trading days breached NYSE continued-listing requirements.
- Minor pointSix-month cure period requires month-end closing and preceding 30-trading-day average prices of at least $1.00.
- Minor point. Forward-looking: it has not happened yet and may not happen.Reverse stock split is among the alternatives Equus intends to consider to address listing noncompliance.
- Minor pointContinued listing remains subject to compliance with the NYSE's other continued-listing standards.
News Explained
If Equus chooses a cure action requiring stockholder approval at a special meeting, the release says the price condition is deemed cured when the share price promptly exceeds
Key Figures
- Minimum average closing price
- $1.00
- Required over a consecutive 30-trading-day period to maintain NYSE listing
- Cure period
- Six months
- Following receipt of the NYSE deficiency notice
- Notice-of-intent deadline
- October 20, 2026
- Company plans to notify the NYSE of its intent to cure
- Monthly cure test
- $1.00 closing price and $1.00 average closing price
- Both thresholds must be met on the last trading day of a calendar month; average uses the preceding 30 trading days
- Stockholder-approval cure condition
- Above $1.00 for at least 30 trading days
- Applies when the cure action requires approval at a special stockholder meeting
Key Terms
reverse stock split financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Company Intends to Regain Compliance with NYSE Rule
Notice Has No Immediate Impact on the Listing or Trading of Equus Common Stock
HOUSTON, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Equus Total Return, Inc. (NYSE: EQS) (“Equus” or the “Company”) announced today that it was notified by the New York Stock Exchange (the “NYSE”) on October 6, 2026, that it is not in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing price of the Company’s Common Stock (“Common Stock”) was less than
The Company plans to notify the NYSE by October 20, 2026 that it intends to cure the average closing stock price deficiency and to return to compliance with the NYSE's continued listing standards. The Company can regain compliance at any time within the six-month period following receipt of the NYSE's notice if on the last trading day of any calendar month during the cure period, the Company has (i) a closing share price of at least
The Company intends to consider available alternatives to cure the stock price noncompliance including, but not limited to, a reverse stock split. Under the NYSE’s rules, if the Company determines that it will cure the stock price deficiency by taking an action that will require stockholder approval at a special meeting of stockholders, the price condition will be deemed cured if the price promptly exceeds
The Company’s Common Stock will continue to be listed and trade on the NYSE during this period, subject to the Company’s ongoing compliance with the NYSE's other continued listing standards. Furthermore, the notice is not anticipated to impact the ongoing business operations of the Company or its reporting requirements with the U.S. Securities and Exchange Commission.
About Equus
The Company is a business development company that trades as a closed-end fund on the New York Stock Exchange under the symbol "EQS". Additional information on the Company may be obtained from the Company’s website at www.equuscap.com.
This press release may contain certain forward-looking statements regarding future circumstances. These forward-looking statements are based upon the Company’s current expectations and assumptions and are subject to various risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements including, in particular, the performance of the Company, including our ability to achieve our expected financial and business objectives, and the other risks and uncertainties described in the Company’s filings with the SEC. Actual results, events, and performance may differ. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as to the date hereof. Except as required by law, the Company undertakes no obligation to release publicly any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. The inclusion of any statement in this release does not constitute an admission by the Company or any other person that the events or circumstances described in such statements are material.
Contact:
Equus Total Return, Inc.
1-888-323-4533
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Why did Equus Total Return receive an NYSE noncompliance notice?
Equus received the notice because its average closing share price was below $1.00 over 30 consecutive trading days. The NYSE notified the company on October 6, 2026, of noncompliance with Section 802.01C of its Listed Company Manual.
Does the NYSE notice mean Equus Total Return stock is being delisted?
No. The notice is a deficiency notice, not a delisting, and has no immediate effect on listing or trading. Equus common stock will continue to trade on the NYSE during the cure period, subject to compliance with the exchange's other continued-listing standards.